

Application No. 09/510,560
Art Unit: 1615

Box CPA
December 16, 2002
Docket No. P 24,375-A-USA

a salt; (iii) an acid halide; or (iv) an acid anhydride, and a second functional group which is: (i) a glyceride; (ii) an acid halide, or (iii) an acid anhydride. Support for this amendment can be found on page 9 of the specification, first full paragraph, as originally filed.

Status of the Claims

This is a Continued Prosecution Application. Claims 1, 3 to 39, 41, 42, 47, and 49 to 51 were pending in the parent application. Claims 41 and 47 have been amended. No claim has been cancelled. Accordingly, there is presented for the Examiner's consideration Claims 1, 3 to 39, 41, 42, 47, and 49 to 51.

Application No. 09/510,560
Art Unit: 1615


Box CPA
December 16, 2002
Docket No. P 24,375-A-USA

Miscellaneous

With respect to the amended claims, enclosed herewith is "Version with Markings to Show Changes Made."

Respectfully submitted,
Synnestvedt & Lechner

December 16, 2002
Date



H. Eric Fischer, Esquire
Registration No. 46,010

Synnestvedt & Lechner LLP
Suite 2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950
(215) 923-4466

M:\EFischer\Elan Corp plc\P-24375 A.USA\preliminary amendment - cpa.wpd

Copy With Markings to Show Changes Made

41. (Once Amended) A process for the manufacture of a composition in solid oral dosage form comprising the step of:

- a) providing a blend of a drug and, as an enhancer[,]:
a) a medium chain fatty acid salt having a carbon chain length of from 6 to 20 carbon atoms [or a salt of]; b) a medium chain fatty acid halide, anhydride, or glyceride derivative which has a carbon chain length of from 6 to 20 carbon atoms; or c) a difunctional medium-chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, which has on one end an acid salt, halide, anhydride or glyceride functional group, and on the other end an acid halide, anhydride or glyceride functional group, or a salt thereof, and which blend also comprises, optionally, another constituent(s), wherein each of said drug, enhancer, and optional constituent(s) is a solid at room temperature; and
- b) forming said solid oral dosage form of the composition from the blend by:
 - i) direct compression of the blend; or
 - ii) granulating the blend to form a granulate for incorporation into said solid

oral dosage form.

47. (Once Amended) A composition in solid oral dosage form comprising a drug and, as an enhancer[,]: (a) a salt [of a], halide, anhydride, or glyceride derivative of a medium chain fatty acid which has a carbon chain length of from 6 to 20 carbon atoms, or a salt thereof; or (b) a difunctional medium chain fatty acid derivative which has a carbon chain length of from 6 to 20 carbon atoms, and wherein one functional group is a salt, halide, anhydride, or glyceride functional group and the second functional group is an acid halide, anhydride or glyceride functional group, and wherein each of said constituents and any other constituent comprising the composition is a solid at room temperature.